Zogenix Inc

NASDAQ:ZGNX   1:51:55 PM EDT
20.81
+0.93 (+4.68%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.16B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.3 Million
Adjusted EPS-$1.03
See more estimates
10-Day MA$20.67
50-Day MA$20.40
200-Day MA$24.78
See more pivots

ZOGENIX, INC. Stock, NASDAQ:ZGNX

5858 HORTON STREET, #455, EMERYVILLE, CA 94608
United States of America
Phone: (510) 550-8300
Number of Employees: 90

Description

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The company's lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.